Small Molecules

27 Dec 2017 FDA APPROVES NANOBIOTIX'S FIRST IMMUNO-ONCOLOGY TRIAL:
27 Dec 2017 Agios Submits New Drug Application to the FDA for Ivosidenib for the Treatment of Patients with Relapsed/Refractory AML and an IDH1 Mutation
23 Dec 2017 Gemphire Therapeutics Announces Initiation of its First NASH Proof-of-Concept Clinical Trial and its Differentiated NASH Program
23 Dec 2017 Novartis drug Tasigna® is approved by FDA as first and only CML therapy with Treatment-free Remission data in its label
22 Dec 2017 RedHill Biopharma Announces Initiation of Phase IIa Study with ABC294640 (YELIVA®) for Cholangiocarcinoma at Mayo Clinic and MD Anderson
22 Dec 2017 FDA Approves SGLT2 Inhibitor STEGLATRO™ (ertugliflozin) and Fixed-Dose Combination STEGLUJAN™ (ertugliflozin and sitagliptin) for Adults with Type 2 Diabetes
22 Dec 2017 Ironwood Pharmaceuticals Initiates Phase II Clinical Trial of sGC Stimulator IW-1701 in Patients with Sickle Cell Disease
22 Dec 2017 Celgene and LYSARC Provide Update on Phase III ‘RELEVANCE’ Study of REVLIMID® in Combination with Rituximab (R2) for the Treatment of Previously Untreated Patients with Follicular Lymphoma
22 Dec 2017 Santen Receives Complete Response Letter from U.S. FDA for Intravitreal Sirolimus (DE-109)
22 Dec 2017 Jazz Pharmaceuticals Submits New Drug Application for Solriamfetol (JZP-110) for Excessive Sleepiness Associated with Narcolepsy and Obstructive Sleep Apnea
22 Dec 2017 U.S. FDA Grants Priority Review to Janssen for Apalutamide as a Treatment for Non-Metastatic Castration-Resistant Prostate Cancer
21 Dec 2017 Arvinas Nominates Oral Clinical Candidate for Estrogen Receptor Degrader Program
21 Dec 2017 Biohaven Enrolls First Patient In Pivotal Trial Of Trigriluzole In Patients With Obsessive-Compulsive Disorder
21 Dec 2017 Denali Therapeutics Announces Advancement and Expansion of Its LRRK2 Inhibitor Clinical Program for Parkinson’s Disease
21 Dec 2017 TARIS and Bristol-Myers Squibb Announce Clinical Trial Collaboration
21 Dec 2017 FDA Accepts New Drug Application For Seysara™ (Sarecycline) For The Treatment Of Moderate To Severe Acne
21 Dec 2017 EU Follows US and Approves Chugai’s ALK Inhibitor "Alecensa®" as First Line Therapy for ALK-Positive Non-Small Cell Lung Cancer
21 Dec 2017 Bayer announces initiation of rolling submission of new drug application in the U.S. for larotrectinib for the treatment of TRK fusion cancers
21 Dec 2017 Achillion Initiates Phase I First-In-Human Study of ACH-5228, a Next-Generation Oral Small Molecule Inhibitor of Complement Factor D
21 Dec 2017 AbbVie's Upadacitinib Shows Positive Results as Monotherapy in Phase 3 Rheumatoid Arthritis Study, Meeting All Primary and Key Secondary Endpoints
21 Dec 2017 Sanifit Announces Last Patient Last Visit completed in Clinical Trial of SNF472 in Patients with Calciphylaxis
20 Dec 2017 Exelixis Announces U.S. FDA Approval of CABOMETYX® (cabozantinib) Tablets for Previously Untreated Advanced Renal Cell Carcinoma
20 Dec 2017 Green Cross Wellbeing Announces BfArM Authorisation to Initiate Phase 2 Study of BST204 for Cancer Cachexia
20 Dec 2017 U.S. FDA Approves Pfizer’s BOSULIF® (bosutinib) for the Treatment of Patients with Newly-Diagnosed Ph+ Chronic Myelogenous Leukemia (CML)
20 Dec 2017 Array BioPharma Announces Strategic Collaboration with Pfizer

La Merie Biologics

FREE Weekly News Bulletin

2016 Sales ofAntibodies & Proteins

New Product Alert

For La Merie Publishing

Top